Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
about
Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesTherapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.Pituitary dysfunction in granulomatosis with polyangiitis.
P2860
Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Con: Should all patients with ...... marily treated with rituximab?
@en
type
label
Con: Should all patients with ...... marily treated with rituximab?
@en
prefLabel
Con: Should all patients with ...... marily treated with rituximab?
@en
P2860
P356
P1476
Con: Should all patients with ...... marily treated with rituximab?
@en
P2093
David R W Jayne
P2860
P304
P356
10.1093/NDT/GFV216
P407
P577
2015-05-21T00:00:00Z